Skip to Main Content


Skip Nav Destination


Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading



Rising Stars in Cancer Immunology

Priority Brief

Peripheral neuropathy has been reported in the context of combination treatment with checkpoint inhibitors and chemotherapeutic agents. The authors show that PD-1/PD-L1 checkpoint inhibition can enhance paclitaxel-induced neuropathic pain by inhibiting neuroimmune PD-1/PD-L1 antinociceptive signaling.

Research Articles

The role of mammary tissue–associated mast cells during breast cancer is poorly defined. Here, the authors uncover a novel gut microbiome–mast cell axis in mammary tissue that enhances early metastatic spread of HR+ tumors.

The tumor microenvironment (TME) of clear cell ovarian cancer is characterized. Immune infiltration and collagen deposition differ based on disease stage, TME localization, and ARID1A status, highlighting the necessity of evaluating multiple features when determining treatment strategy.

Two distinct populations of TIM4-expressing tumor-associated macrophages localize to tertiary lymphoid structures or body cavities and either promote T-cell responses or induce immunosuppression, respectively, suggesting novel treatment approaches and relevance for selection of immune therapy.

CAR T cells targeting tumor-associated macrophages are found to stimulate IFNγ-dependent endogenous T cell–mediated antitumor activity in mouse models of solid tumors. CAR T cell depletion of macrophages shows promise as a strategy for tumor antigen–agnostic immunotherapy.

Tumors expressing FasL can kill antitumor T cells. The enhanced antitumor effects of CAR T cells armed with secreted Fas decoys reported here suggest a way to improve clinical efficacy of cellular therapies in solid tumors.

The mechanisms underlying hyperprogressive disease (HPD) associated with PD-1 blockade are unclear. The authors develop a way to reproduce HPD by partially eliminating CD8+ T cells with NIR-PIT, creating a regulatory T cell–dominant tumor microenvironment permissive of tumor growth.

ICBatlas provides search, browse, and visualization functions for integrated and reanalyzed results based on large-scale transcriptome data from immune checkpoint blockade (ICB)–treated patient samples. This resource serves as a one-stop solution for transcriptome data–related research on ICB therapy.

Bone marrow T-cell clonal expansion, immune phenotypes, and specificities at the single-cell level were determined in treatment-naïve multiple myeloma. Dominant T-cell clones rarely recognize antigens presented on myeloma cells, are not neoantigen-specific, and show low immune checkpoint expression.

Close Modal

or Create an Account

Close Modal
Close Modal